Table 1 . Design, Patient Characteristics, IVIG Doses and Trial Duration .

RCT Study	Design	N	MS duration (years)	Mean age (years)	EDSS	Trial duration	Dose (months)
Fazekas et al. (1997)	PG	IVIG:75 Placebo:73	IVIG:6.8 Placebo:7.3	IVIG:36.7±2.4 Placebo:37.2±2.3	IVIG:3.3 Placebo:3.3	24	0.15–0.2g/kg
Achiron et al. (1998)	PG	IVIG:20 Placebo:20	IVIG:4.1 Placebo:3.95	IVIG:35.4±2.1 Placebo:33.8±2.4	IVIG:2.9 Placebo:2.82	24	0.4g/kg
Strasser et al. (2000)	PG	IVIG:75 Placebo:75	IVIG:6.8±4.6 Placebo:7.3±5.7	IVIG:36.7±10.4 Placebo:37.3±9.8	IVIG:3.33±1.39 Placebo:3.37±1.67	24	0.2g/kg
Lewanska et al. (2002)	PG	IVIG:17 IVIG:15 Placebo:17	IVIG:10.7±7.57 IVIG:7.2±5.48 Placebo:7.5±4.7	IVIG:38±6.96 IVIG:31.1±6.08 Placebo:41.8±6.98	IVIG:3.0±1.35 IVIG:3.0±2.08 Placebo:2.97±1.58	12	0.2g/kg 0.4g/kg
Kocer et al. (2004)	PG	IVIG:12 Placebo:12	IVIG:2-14 Placebo:2-14	IVIG:22-56 Placebo:22-39	IVIG:2.46±1.82 Placebo:1.96±1.60	9	0.4g/kg
Fazekas et al. (2008)	PG	IVIG:44 IVIG:42 Placebo:41	IVIG:2.8±1.9 IVIG:2.7±2.1 Placebo:2.3±1.5	IVIG:31.9±7.5 IVIG:34.4±7.9 Placebo:33.0±8.7	IVIG:1.8±0.9 IVIG:2.1±1.1 Placebo:2.1±1.2	12	0.2g/kg 0.4g/kg

PG= parallel groups; IVIG= intravenous immunoglobulin; EDSS= Expanded Disability Status Scale; MS= multiple sclerosis